Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Common-Size Income Statement

Beginner level

Bristol-Myers Squibb Co., common-size consolidated income statement

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Net product sales 97.18 96.29 95.66 92.69 91.12
Alliance and other revenues 2.82 3.71 4.34 7.31 8.88
Revenues 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of products sold, excludes amortization of acquired intangible assets -27.69 -30.90 -29.02 -29.20 -25.46
Gross margin 72.31% 69.10% 70.98% 70.80% 74.54%
Marketing, selling and administrative -18.02 -18.63 -20.17 -22.56 -25.28
Research and development -26.21 -23.52 -28.12 -30.86 -25.43
IPRD charge, MyoKardia acquisition -26.90 0.00 0.00 0.00 0.00
Amortization of acquired intangible assets -22.79 -4.34 0.00 0.00 0.00
Operating income (loss) -21.60% 22.62% 22.69% 17.39% 23.83%
Interest expense -3.34 -2.51 -0.81 -0.94 -0.86
Contingent consideration 4.13 -2.00 0.00 0.00 0.00
Royalties and licensing income 3.59 5.20 6.00 6.50 3.70
Equity investment gains (losses) 2.89 1.05 -1.86 0.47 0.21
Integration expenses -1.69 -1.59 0.00 0.00 0.00
Provision for restructuring -1.25 -1.15 -0.58 -1.41 -0.56
Litigation and other settlements 0.46 -0.29 -0.34 2.34 -0.24
Transition and other service fees 0.35 0.14 0.05 0.18 1.23
Investment income 0.28 1.77 0.77 0.61 0.50
Reversion excise tax -0.18 0.00 0.00 0.00 0.00
Divestiture gains 0.13 4.47 0.79 0.79 2.96
Intangible asset impairment -0.05 -0.06 -0.28 0.00 -0.08
Pension and postretirement 0.03 -6.12 0.12 -0.78 -0.47
Acquisition expenses 0.00 -2.51 0.00 0.00 0.00
Loss on debt redemption 0.00 0.00 0.00 -0.52 0.00
Other 0.08 0.00 -0.09 0.08 0.23
Other income (expense), net 5.44% -3.59% 3.77% 7.31% 6.61%
Earnings (loss) before income taxes -16.16% 19.03% 26.45% 24.70% 30.45%
Provision for income taxes -5.00 -5.79 -4.53 -20.00 -7.25
Net earnings (loss) -21.16% 13.23% 21.93% 4.69% 23.20%
Noncontrolling interest -0.05 -0.08 -0.12 0.15 -0.26
Net earnings (loss) attributable to BMS -21.20% 13.15% 21.81% 4.85% 22.94%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co.’s operating income (loss) as a percentage of revenues decreased from 2018 to 2019 and from 2019 to 2020.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co.’s earnings (loss) before income taxes as a percentage of revenues decreased from 2018 to 2019 and from 2019 to 2020.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co.’s net earnings (loss) attributable to BMS as a percentage of revenues decreased from 2018 to 2019 and from 2019 to 2020.